Literature DB >> 6802863

The costs and effects of screening for cancer among asbestos-exposed workers.

B J McNeil, D M Eddy.   

Abstract

Several million workers previously exposed to asbestos are at risk each year for developing asbestosis or cancer as a result of this exposure. We have reviewed the data on the general effectiveness of screening for the two most common cancers found in these workers (lung cancer and colo-rectal cancer) and have compared the relative benefits expected from screening workers for colon or lung cancer 10, 15, 20 or 25 yr after their initial exposure. Although lung cancer is common, there is little evidence at present that screening for this disease is effective in reducing mortality. Colon cancer is less common, there is more evidence that screening is effective, and the relatively high risk of dying from this disease in asbestos workers makes screening useful. The cost per additional year of life extended by screening is only a few hundreds of dollars, making colon cancer screening programs for asbestos workers considerably more cost-effective than most other screening programs. We conclude that occupational safety agencies should consider implementing screening programs for colon cancer in workers exposed to asbestos over 10 yr ago.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6802863     DOI: 10.1016/0021-9681(82)90006-6

Source DB:  PubMed          Journal:  J Chronic Dis        ISSN: 0021-9681


  3 in total

1.  Biological monitoring and medical screening at the workplace in the EC countries.

Authors:  K Rasmussen; P Lunde-Jensen; O Svane
Journal:  Int Arch Occup Environ Health       Date:  1991       Impact factor: 3.015

Review 2.  Does asbestos exposure cause gastrointestinal cancer?

Authors:  D S Levine
Journal:  Dig Dis Sci       Date:  1985-12       Impact factor: 3.199

3.  Screening blood donors for human immunodeficiency virus antibody: cost-benefit analysis.

Authors:  R S Eisenstaedt; T E Getzen
Journal:  Am J Public Health       Date:  1988-04       Impact factor: 9.308

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.